Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Israel's Super-Pharm, Pfizer Form JV For On-Line Viagra Sales

This article was originally published in PharmAsia News

Executive Summary

Pfizer and Israeli drug maker Super-Pharm have set up a joint venture to market the best-selling Viagra (sildenafil) erectile dysfunction drug on the Internet to fight counterfeits

Pfizer and Israeli drug maker Super-Pharm have set up a joint venture to market the best-selling Viagra (sildenafil) erectile dysfunction drug on the Internet to fight counterfeits.

The deal calls for Super-Pharm to use its Web site to market the drug and deliver itdirectly to men who buy it with a valid prescription. On-line buyers would receive a 9% discount from the list price. Super-Pharm said the main intention of the venture is to compete with counterfeits of the popular drug, a major problem in Israel. (Click here for more)

"Super-Pharm, Pfizer Set Up On-Line Viagra Venture" - Globes (Israel) (0/13/11)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC078990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel